I appreciate the clarification. I wasn't aware of that distinction but, in my opinion, when we are talking about drugs, one mistake is one mistake too many. Even though we aren't talking about the same type of label, as you just explained so well, there were safety and regulatory problems in that case. The report deals with that.
In your action plan and in the steps you are taking, is that type of situation generally taken into account in finding long-term safety and regulatory solutions?